The purpose of this study was to investigate the likelihood of achieving both LDL and HDL goals in the primary prevention of cardiovascular disease using an epidemiologic sample of United States residents by comparing simvastatin to a combined regimen of lovastatin/extended-release niacin. An additional objective was to estimate the cost-effectiveness of each product and the incremental cost-effectiveness ratio between regimens. METHODS: A decision analytic model was developed to compare the cost-effectiveness of simvastatin and lovastatin/extended-release niacin. Product labeling estimated the change in cholesterol concentrations and the frequency of clinically important adverse events. The Third National Health and Nutrition Examination Survey (NHANES) adult data were used to estimate population cholesterol levels. Average wholesale price was used for medication costs. RESULTS: The NHANES data revealed there were 256 patients (10.5%) that required a LDL goal of <160 mg/dL, 1268 (52.2%) that required a goal of <130 mg/dL, and 906 patients (37.3%) that required a goal of <100 mg/dL. For both the 130 mg/dL and 100 mg/dL LDL goal analyses (and HDL ≥40 mg/dL), lovastatin/extended-release niacin had higher success rates and lower average total costs than simvastatin. Simvastatin had the highest success rate in achieving LDL level <160 mg/dL and HDL ≥40 mg/dL. However, the average total health system cost (medications, physician visit costs, and laboratory costs) to use simvastatin was approximately twice that of lovastatin/extended-release niacin ($665 versus $332). CONCLUSIONS: For LDL goals <130 and <100 mg/dL (and HDL ≥40 mg/dL), lovastatin/ extended-release niacin was both more successful and less costly than simvastatin.
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DETERMINANTS OF COST EFFECTIVENESS IN CLINICAL GUIDELINES FOR CARDIOVASCULAR PROPHYLAXIS WITH STATINS
Milne RJ, Gamble GD University of Auckland, Auckland, New Zealand OBJECTIVES: To quantify the major determinants of population cost effectiveness of clinical guidelines for risk screening and prevention of cardiovascular disease (CVD) with "statin" therapy. METHODS: Risk profiles were collected for 4704 men age 35-84 y and 1216 women age 45-84 y without CVD. 5-year risk of a cardiovascular hospital admission for each individual was calculated using a Framingham risk equation. The predicted number of incident events in 5 years was scaled by age and gender to the 2001 NZ census population and integrated over age groups. Costs, benefits and cost effectiveness were estimated at treatment thresholds Tc/HDLc = 4.0 to 6.5 and 5 y risk 10% or 15%; and screening age thresholds 35/45 (M/F) to 50/60 y and treatment adherence 50% to 84%. RESULTS: In the NZ population of 784 K men age 35-84 y and 558 K women age 45-84 y, at treatment thresholds of Tc/HDLc = 5.5 and 15% 5 y risk, 56 K men and 20 K women would be eligible for prophylaxis. Compared to no intervention, 5 y prophylaxis with 84% adherence would avert 3875 incident cardiovascular events and add 3712 life years at an incremental cost of $NZ29 M and ICER < $NZ8000 ($US4000) per event avoided or LYG (discounted at 5%). The ICERs change 2 to 3-fold with treatment adherence (50% vs 84%), threshold lipid ratio (4.5 or 6.5 vs 5.5) and threshold screening age (50/60 vs 35/45) but less than 25% with treatment efficacy (24% vs 30%) and the 5 y risk treatment threshold (10% vs 15%). The cost per LYG also depends strongly on the 5 y cardiovascular fatality rate and the discount rate. CONCLUSIONS: Prophylaxis with 'statins' is very cost effective at current drug prices and clinically realistic treatment thresholds. Clinical guidelines for cardiovascular prophylaxis should focus on the threshold age for risk screening, the threshold lipid ratio and methods for enhancing treatment adherence.
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COST EFFECTIVENESS ANALYSIS OF HMG-COA REDUCTASE INHIBITORS IN A MEDICAID POPULATION
MacLean EA, Moffitt CM Pfizer, Inc, Wakefield, RI, USA OBJECTIVES: This retrospective analysis of publicly available pharmacy claims data evaluates prescription trends and estimates cost effectiveness of statins based on acquisition cost and LDL-C lowering capacity. METHODS: Massachusetts Medicaid statin utilization data for 2001 was obtained from the Centers for Medicare and Medicaid (CMS) website (www.cms.gov/ medicaid/drugs/drug5.htm). Units per prescription, average cost per prescription, marketshare, days supply, and average cost per day were calculated. The annual cost per percent LDL-C reduction was calculated by dividing the annual cost by the percent LDL lowering capacity. These methods modeled the CURVES study and a subsequent pharmacoeconomic analysis by Hilleman, et al. LDL-C lowering capacity was obtained from the package insert for drug strengths not studied in the CURVES study. Drugs were compared based on equipotent LDL-C lowering capacity. Acquisition costs were not reflective of manufacturer rebates. RESULTS: The statin market was comprised of atorvastatin at 67.33%, simvastatin at 14.76%, pravastatin at 10.74%, lovastatin at 3.91% and fluvastatin at 3.25%. Atorvastatin 10 mg, the most commonly prescribed agent (40.02%), was the most cost effective agent with an annual patient cost per percent LDL-C reduction of $17.12. In comparison, the costs per percent LDL-C reduction for equipotent strengths of other statins were fluvastatin 80 mg at $17.93, simvastatin 20 mg at $36.84, pravastatin 40 mg at $37.66 and lovastatin 40 mg at $47.29. Acquisition costs per unit for these agents were $1.78, $1.72, $3.53, $3.51 and $4.02, respectively. CONCLUSION: Acquisition cost is one component in evaluating cost of therapy. However, in this analysis, among equipotent agents, the agent with the lowest acquisition cost was not the most cost effective. Attempts to quantify cost effectiveness should be made when reviewing the statin class.
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COST-EFFECTIVENESS OF TREATING BY SIMVASTATIN 40 MG/DAY HIGH VASCULAR RISK PATIENTS: AN ECONOMIC EVALUATION BASED ON THE HEART PROTECTION STUDY
Fagnani F 1 , Lafuma A 2 , Souchet T 3 1 CEMKA, Bourg la Reine, France; 2 CEMKA-EVAL, Bourg La Reine, France; 3 Merck Sharp & Dohme-Chibret, Paris, France OBJECTIVES: Estimate the cost-effectiveness ratio in France of treating high vascular risk patients with simvastatin. METHODS: Data on efficacy and resources consumed were extracted from the published results of the MRC/BHF Heart Protection Study (HPS) performed in UK. HPS compared the occurrence of total and CHD deaths, major vascular events (MVE), and major coronary events (MCE) in more than 20,000 patients with high vascular risk (patients with diabetes, history of stroke or other cerebrovascular disease, peripheral arterial disease, or with CHD). Patients were randomly assigned to receive simvastatin or placebo and followed at least for five years. The cost-effectiveness analysis was performed using French unit costs. The survival benefit over the study period was estimated from the HPS results. Direct costs included the extra costs of simvastatin and the benefit associated with avoided vascular events. Indirect costs were not considered. Costs and benefit were discounted at 5%. RESULTS: All-cause mortality was reduced by 13% (RR = 0.87, p = 0.0003). There was a discounted survival benefit of 0.040 year per included patient. There were highly significant reductions of about one quarter in the risk of first event rate of MVE (RR = 0.76, p < 0.0001) and of MCE (RR = 0.73, p = 0.0001). The absolute value of the percentage of avoided event during the 5-year period in the simvastatin group was 5.4% for any major vascular event, 2,1% for non fatal MI, 1.3% for non fatal stroke, 2.4 % for revascularisation, 1.2% for fatal MI and 0.2% for fatal stroke. The discounted extra cost of simvastatin was estimated at €1994 ($1 = €1) taking into account the statins used in the placebo group. This cost was reduced to €1031 by considering the direct cost associated with avoided vascular events. Cost-effectiveness ratio was then estimated at €23,678 per life year gained (€22,000 to €50,000 in the different subcategories of patients, ratios well accepted as being cost-effective). CONCLUSIONS: Treat-ment with simvastatin in different subcategories of patients with high vascular risk is cost-effective in the French setting. OBJECTIVES: Studies examining costs following myocardial infarction (MI) have been limited by short follow-up, small sample sizes, restricted patient populations, or failure to include hospital, physician, or market characteristics. In a national sample with extensive supplemental data, we sought to identify the baseline factors predicting higher costs in the year following MI. METHODS: Elderly acute MI patients totaling 84,373 (90% white, 49% female) in the Cooperative Cardiovascular Project were linked to Medicare Part A claims, AHA Hospital Surveys, the CMS directory of physician specialties, and the CMS Hospital Wage Index File. Medicare charges were converted to costs using institutional cost to charge ratios. Associations with admission episode and one-year log-transformed costs were assessed by regression analysis with robust standard errors. RESULTS: Mean cost was $12,956 (median $8,833) for the admission episode and $19,597 (median $13,583) at one year. Patient characteristics accounted for 11% of the admission and one-year cost variation. Patient variables most highly associated with one-year costs included anterior MI, CHF, COPD, renal insufficiency, diabetes, and shock. Older age (age 80 years) was most strongly associated with lower costs. After adding hospital, physician, and market variables, the models explained 22% of admission and 17% of the one-year cost variation. Teaching hospitals and care by a cardiologist were both associated with higher one-year costs. While patient death was associated with lower admission episode costs, death after the initial episode was associated with higher one-year costs. CON-CLUSION: In models examining the baseline predictors of one-year costs following MI, patient characteristics account for approximately twice the cost variation accounted for by other baseline variables.
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BASELINE PREDICTORS OF ONE-YEAR COSTS AFTER ACUTE MYOCARDIAL INFARCTION IN THE ELDERLY
